PSP Research’s Summit Therapeutics SMMT Stock Holding History

PSP Research’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,223	Closed	-$194K	–	87
2026 Q1	$194K	Buy	+10,223	New	+$165K	0.14%	73

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

PSP Research's SMMT Position: Q2 2026 in Review

PSP Research sold out of Summit Therapeutics (SMMT) in Q2 2026, closing a stake of 10,223 shares — an estimated $194K sold.

PSP Research first reported a position in SMMT in Q1 2026 and held it in 1 quarter. The position peaked at $194K in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

PSP Research reported no remaining Summit Therapeutics position as of Q2 2026 after selling out during the quarter.
PSP Research sold 10,223 Summit Therapeutics shares in Q2 2026, an estimated $194K.
PSP Research first reported a position in Summit Therapeutics in Q1 2026 and held it in 1 quarter.
PSP Research's Summit Therapeutics position peaked at $194K in Q1 2026.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.